Ann Marie Pendergast, PhD, has received a two-year $150,000 Lung Cancer Research Foundation grant to continue her laboratory work “uncovering novel vulnerabilities to treat small cell lung cancer therapy resistance.”

Li Lan, MD, PhD, researches how cancer cells respond to DNA damage through DNA repair mechanisms. The major focus of her lab — previously situated at The Krantz Family Center for Cancer Research, Mass General Cancer Center — is drug development.

Brent Hanks, MD, PhD, is working to develop new pharmacologic and genetic strategies to overcome immunotherapy resistance and investigating the mechanisms that contribute to some immunotherapy-associated toxicities.

On Tuesday, Oct. 17, DCI's Valarie Worthy, MSN, RN, and Steven Patierno, PhD, will participate in the first of a series of in-person meetings of the President’s Cancer Panel in New Orleans.

Mary Jo Turk, PhD, co-director of the Immunology and Cancer Immunotherapy Program, Norris-Cotton Cancer Center, Dartmouth Geisel School of Medicine, presents “Identifying precursors of resident memory T cells in cancer.”

The White House Cancer Moonshot program announced its support for and commitment to several new projects to "end cancer as we know it," including a new initiative led by TOUCH, the Black Breast Cancer Alliance (co-founded by Valarie Worthy, RN).

Angelo Moore, PhD, MSN, RN, NE-BC, director of the DCI Community Outreach, Engagement, and Equity program Office of Health Equity, has been named a Fellow of the American Academy of Nursing (AAN). Moore, along with four other nurses at Duke.

As the 2023 Annual Meeting of the American Society of Clinical Oncology was wrapping up this week, Chief Patient Experience and Safety Officer at Duke Cancer Institute Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO, was already in planning mode.

The DCI Community Outreach, Engagement, and Equity program, with site sponsors Lincoln Community Health Center and Duke Primary Care Croasdaile, presents its annual Men's Health Screening event.

Angeles Alvarez Secord, MD, MHSc, was officially installed as president of the Society of Gynecologic Oncology at the Society's Annual Meeting, held in March. Her term lasts for a year.

DCI has announced the launch of a new Cancer Health Disparities & Equity lecture series. The series is a collaboration between DCI’s Disparities SPORE and DCI’s Community Outreach, Engagement, and Equity Program.

The annual Women's Health Awareness Day Conference, sponsored by the NIH National Institutes of Environmental Health Sciences, will be held at the NCCU campus in Durham. This is the first time the event will be held in person since 2019.

Daniel Nussbaum, MD, is one of 12 young surgeons nationwide to be selected for the 2023 Early-Stage Surgeon Scientist Program. His research focuses on pancreatic cancer.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Betty Tong, MD, BME, MSME, MD, MHS, is a recipient of the inaugural “Extraordinary Women in Cardiothoracic Surgery Award” established by the Society of Thoracic Surgeons and Women in Thoracic Surgery.

DCI is joining a new initiative with the Global Pediatric Brain Tumor Network, Bayer, the National Brain Tumor Society, other institutions, and Africa partners to "create an equitable ecosystem of care for pediatric brain cancer."

With 40+ journals and grant panel contributions, 159 publications, 60+ committees, 21+ research projects, 159 publications, and 250 lectures, Susan Dent, MD, is "a unifying voice in the field of cardio-oncology."

DCI oncologists are blazing the trail on the national stage with their inroads in breast and gynecologic cancer research, treatment, and advocacy.

Cancer epidemiologist Electra D. Paskett, PhD, associate director of Population Sciences and Community Outreach at the Comprehensive Cancer Center of The Ohio State University, is the featured speaker.

The Radiation Research Society has bestowed its highest honor — the Failla Memorial Lecture Award — on Michael B. Kastan, MD, PhD, executive director of Duke Cancer Institute and William and Jane Shingleton Professor, Pharmacology and Cancer Biology.